前瞻性注册研究中进展性纤维化间质性肺疾病的患病率与特征
研究基于加拿大肺纤维化注册(2015–2020)纳入2746例纤维性间质性肺疾病患者,按预设标准定义进展性纤维化间质性肺疾病(PF-ILD)。随访24个月内50%患者符合PF-ILD标准,IPF与纤维性过敏性肺炎进展比例相近,而结缔组织病相关ILD进展相对延迟。年龄增长、男性、胃食管反流及基线肺功能较低与进展独立相关。
要点
- 纤维性间质性肺疾病患者24个月内约半数符合PF-ILD标准。
- 纤维性过敏性肺炎与IPF的进展时间相似,CTD-ILD进展相对延迟。
- 年龄、男性、胃食管反流和低基线肺功能与进展独立相关。
核心结论
- 纤维性间质性肺疾病中进展常见,纤维性过敏性肺炎与IPF的进展患病率相似。
研究设计与样本
- 前瞻性注册研究,纳入加拿大肺纤维化注册2015–2020年2746例纤维性间质性肺疾病患者。
主要发现
- 2746例中1376例(50%)在诊断后24个月内符合PF-ILD标准。
- IPF患者427例(59%)、纤维性过敏性肺炎125例(58%)、不可分类ILD 281例(51%)、CTD-ILD 402例(45%)符合PF-ILD标准。
- 与IPF相比,纤维性过敏性肺炎进展时间相似(HR 0.96,95%CI 0.79–1.17),不可分类ILD进展延迟(HR 0.82,95%CI 0.71–0.96),CTD-ILD进展延迟(HR 0.65,95%CI 0.56–0.74)。
- IPF患者66%接受抗纤维化治疗;纤维性过敏性肺炎、CTD-ILD和不可分类ILD分别有49%、61%和37%接受免疫调节治疗。
- 年龄增长、男性、胃食管反流病和较低基线肺功能与进展独立相关。
关键数值与推荐
- PF-ILD定义为诊断后24个月内相对FVC下降≥10%、死亡、肺移植,或相对FVC下降≥5%且<10%合并呼吸症状加重或胸部CT纤维化加重中的任意两项。
临床怎么用
- 常规收集的年龄、性别、胃食管反流和基线肺功能等变量有助于识别进展风险较高的纤维性间质性肺疾病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by progressive physiological, symptomatic and/or radiographic worsening. The real-world prevalence and characteristics of PF-ILD remain uncertain. METHODS: Patients were enrolled from the Canadian Registry for Pulmonary Fibrosis between 2015 and 2020. PF-ILD was defined as a relative forced vital capacity (FVC) decline ≥10%, death, lung transplantation or any two of: relative FVC decline ≥5% and <10%, worsening respiratory symptoms or worsening fibrosis on computed tomography of the chest, all within 24 months of diagnosis. Time-to-event analysis compared progression between key diagnostic subgroups. Characteristics associated with progression were determined by multivariable regression. RESULTS: Of 2746 patients with fibrotic ILD (mean±sd age 65±12 years; 51% female), 1376 (50%) met PF-ILD criteria in the first 24 months of follow-up. PF-ILD occurred in 427 (59%) patients with idiopathic pulmonary fibrosis (IPF), 125 (58%) with fibrotic hypersensitivity pneumonitis (HP), 281 (51%) with unclassifiable ILD (U-ILD) and 402 (45%) with connective tissue disease-associated ILD (CTD-ILD). Compared with IPF, time to progression was similar in patients with HP (hazard ratio (HR) 0.96, 95% CI 0.79-1.17), but was delayed in patients with U-ILD (HR 0.82, 95% CI 0.71-0.96) and CTD-ILD (HR 0.65, 95% CI 0.56-0.74). Background treatment varied across diagnostic subtypes, with 66% of IPF patients receiving antifibrotic therapy, while immunomodulatory therapy was utilised in 49%, 61% and 37% of patients with CHP, CTD-ILD and U-ILD, respectively. Increasing age, male sex, gastro-oesophageal reflux disease and lower baseline pulmonary function were independently associated with progression. CONCLUSIONS: Progression is common in patients with fibrotic ILD, and is similarly prevalent in HP and IPF. Routinely collected variables help identify patients at risk for progression and may guide therapeutic strategies.
引用
- Hambly N, Farooqi MM, Dvorkin-Gheva A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022. PMID: 35273032. doi:10.1183/13993003.02571-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。